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Introduction
In many African countries, HIV has
reversed previously recorded declines in
child mortality. Worldwide, children ac-
count for 18% of HIV-related deaths and
15% of HIV infections each year [1–3], an
estimated 2.3 million children are infected,
and 730,000 urgently need antiretroviral
therapy (ART), which only about 275,000
currently receive. The mortality of un-
treated pediatric patients is very high in
the first 2 years of life, and reaches 80% by
age 5 [4]. While the number of children
under age 15 in low- and middle-income
countries receiving ART rose dramatically
between 2005 and 2007 (Figure 1), it is
nonetheless evident that those children
currently on treatment still represent only
a small proportion of those who need it.
Coverage will need to be greatly expanded
if the global community’s goal of providing
ART to 80% of children in need by 2010
is to be met [1].
As more low-cost fixed-dose combina-
tion antiretrovirals (ARVs) for children
become available, the issue of access to
medication is less of an impediment to
treatment (Table 1). Why then are so few
children in developing countries on ART?
We propose that the primary reason is
insufficient identification of infected chil-
dren. There are many causes for this—
including poor coverage of services for
prevention of mother-to-child transmission
(PMTCT), poor linkages to infant testing
programs, provider uncertainty on how
best to diagnose and treat infants, and
insufficient numbers of pediatric HIV
treatment sites—but the end result is that
many infected children are either never
identified or lost from the system before
they can be enrolled into care. We believe
it is essential for national HIV programs to
recognize that HIV testing and counseling
systems designed for adults do not meet
the needs of children. The time has come
to develop and implement specific strate-
gies to increase opportunities for children
to access HIV testing, especially in sub-
Saharan Africa.
As criteria for treatment initiation
evolve and ART programs are scaled up
in resource-limited settings, the need to
expand HIV testing will become more
urgent. Surveys in sub-Saharan Africa
document 39% of adult men and women
as having at some time been tested and
received their results, up from 15% just 2
years before [3]. However, even when
strong adult testing programs exist, access
to pediatric testing remains low. The 2004
World Health Organization (WHO) HIV
testing guidelines did not identify children
as a specific target group for testing [5].
More recent WHO guidance on provider-
initiated HIV testing provides direction
on how to overcome barriers to testing
children but offers little on how to
operationalize pediatric testing [6].
Data from the South African CHER
study highlight the survival benefit of early
treatment for infants, showing an overall
75% decline in mortality in those infants
who were started on ART immediately
after diagnosis [7]. In response, the WHO
has changed its treatment recommenda-
tions, calling for treatment of all infected
infants under 12 months of age, irrespec-
tive of clinical stage [8]. This is a critical
advance in treatment policy, which na-
tional AIDS control programs should
adopt as soon as possible. But without
better ways to identify infected infants, the
policy alone will not change the treatment
landscape in the short term. Although
infant diagnosis is now available in many
PMTCT programs, at current rates of
PMTCT coverage, the majority of HIV-
infected infants are born to mothers who
were never tested and never received
PMTCT prophylaxis. These infants are
very unlikely to be identified and get on to
treatment without targeted testing strate-
gies. Scale up of testing programs for
children will no doubt require investment
in key areas such as training and support
for providers, improvement of laboratory
facilities and referral networks, and com-
munity mobilization, but such investments
are necessary to reduce the substantial
mortality of HIV in children.
Because of the marked survival advan-
tage among those identified and treated in
a timely manner, the US Centers for
Disease Control and Prevention has rec-
ommended routine HIV testing for US
adults during contact with medical facili-
ties [9]. This represents a clear shift away
from voluntary testing (which emphasizes
personal choice) toward an emphasis on
the public and individual health benefits of
improved identification and control of
HIV disease and prevention of HIV
transmission. Of course, success in oper-
ationalizing these recommendations de-
pends on a well-functioning health care
system—which does not exist in many of
the countries most affected by the AIDS
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tions have not been widely implemented in
the most affected parts of the world, where
making a diagnosis is most critical, partic-
ularly in children.
Building an Approach to
Pediatric Testing
Current approaches to testing infants
and children center on PMTCT pro-
grams. New approaches should build on
the considerable success realized by
PMTCT while its shortcomings are rec-
ognized. Routine testing of newborns may
be an appropriate approach to identify
infants missed by PMTCT programs,
particularly in countries with high preva-
lence, while more targeted testing of
infants and children at greater risk may
be more cost effective for lower-prevalence
countries. Regardless of the approach,
there are significant challenges to testing
children for HIV. In infants younger than
18 months, the persistence of maternal
antibodies, the lack of appropriate labora-
tory facilities for PCR testing, the cost of
assays, and the need to repeat PCRs in
infants who are exposed to infected breast
milk [10], make it difficult to implement
infant diagnosis programs. WHO esti-
mates that, in 2007, only 8% of infants
known to be HIV-exposed were tested for
HIV within the first 2 months of life [11].
Waiting for infants to develop symptoms
or become old enough to test using
standard rapid tests is not ideal but has
become the norm in many places, result-
ing in children tested late in the course of
their infection, when ART may be less
effective.
Parental attitudes towards testing are
important to ensure success, but anecdotal
reports suggest that many parents are
apprehensive about subjecting their chil-
dren to HIV tests, especially when they are
unsure of their own HIV status [12].
Equally important is the issue of what
informed consent means for pediatric
patients and their caregivers; the complex-
ities of designing testing programs for
children who neither seek out nor neces-
sarily understand the consequences of a
test; and the ethics of testing children who,
if HIV positive, would indicate the moth-
er’s status as well. As pediatric testing
Summary Points
N Expansion of prevention of mother-to-child transmission in resource-limited
settings remains a challenge.
N In many countries, most HIV-exposed infants do not benefit from PMTCT
programs, which results in a 30% or more transmission rate.
N Vertically infected infants not diagnosed in the context of PMTCT are rarely
diagnosed until symptomatic with HIV, resulting in increased morbidity and
mortality.
N Infant and pediatric testing programs are needed until PMTCT challenges are
overcome or universal treatment of HIV-infected pregnant women becomes the
norm.
Figure 1. Number of children under 15 receiving antiretroviral therapy in low- and middle-income countries, 2005–2007. Source:
UNICEF calculations based on data collected through the PMTCT and Paediatric HIV Care and Treatment Report Card process and reported in UNICEF
Children and AIDS. 3
rd stocktaking report 2008, pp. 34–42 (http://data.unaids.org/pub/Report/2008/20081201_3rd_stocktaking_summary_en.pdf)
[20]. Regions were recalculated according to UNICEF classification of regions.
doi:10.1371/journal.pmed.1000285.g001
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cially important to consider WHO guide-
lines which recommend that children be
involved in the decision to be tested as
much as possible, stressing that parental
consent is always required and that the
decision to test should be voluntary.
Furthermore, in circumstances of extreme
disadvantage, such as with orphans and
vulnerable children, care must be taken to
ensure that HIV testing does not cause
harm because of the greater risk of
discrimination and exploitation that these
children face. This would require training
and support for providers unfamiliar or
uncomfortable with these situations.
Despite the inherent complexities, we
believe that a focus on child testing apart
from PMTCT is long overdue, beginning
with national policies offering a multi-
tiered approach to make pediatric HIV
testing a routine element of care, and
implementation support to make this a
reality. We are not advocating universal
screening of all newborns and infants,
particularly in countries with lower prev-
alence, rather preferring more cost-effec-
tive, targeted approaches that consider
higher diagnostic probabilities in different
circumstances.
The following strategies, while not an
exhaustive list, might result in improved
access to testing. Given the very high
mortality associated with HIV in children,
even minimal attention to the develop-
ment of a pediatric testing strategy might
result in substantial decreases in morbidity
and mortality.
Entry Points for Testing
Two groups of strategies that may be
useful for case finding of children missed
by PMTCT are presented here. First-tier
strategies use existing systems to incorpo-
rate pediatric HIV testing into established
entry points to care, whereas second-tier
strategies require the development of new
programs or systems to actively seek out
and diagnose infected children and link
them to care (Figure 2). First-tier ap-
proaches include variations of provider or
program-initiated testing such as testing
newborns when they present for immuni-
zations—which may prove cost-effective in
countries with high HIV prevalence. In
such hyperendemic settings, an initial
rapid test could be used as a screen to
test mothers or their newborns, with a
subsequent PCR for infants who test
positive or whose mothers are positive.
While such screening is potentially expen-
sive, higher prevalence rates, and thus
higher rates of diagnosis, may justify the
increased costs. One study of routine
testing in immunization clinics found that
testing was well accepted and identified a
large number of exposed children with an
overall seropositivity rate of 10% [13]. In
lower-prevalence settings, connecting the
offer of testing to points of care where the
concentration of infected children is likely
to be higher such as pediatric inpatient
wards, nutrition rehabilitation units, and
tuberculosis clinics may be effective. In
one recent report, 80% of parents accept-
ed testing in pediatric inpatient wards,
yielding a seroprevalence rate of 29%
[14]. In Zambia, children admitted to the
malnutrition ward were found to have
high HIV prevalence rates (Marc Bulterys,
personal communication). Medical set-
tings, while an obvious point of contact,
are not the only venues through which to
reach affected children. Community orga-
nizations, especially those serving orphans
or adults living with HIV, can also be
important partners in expanding access to
pediatric testing.
Second-tier approaches might include
door-to-door or in-home testing, which
may be especially useful for populations
that are infrequent clinic attendees or
simply lack access to care. Variations of
social network testing, in which friends
and acquaintances of HIV-infected per-
sons or those at higher risk are targeted for
testing, are promising strategies in US
adults [15]. Such strategies could be
adapted so that families affected by HIV
are counseled to refer people within their
families or networks, including children,
for testing. Similarly, community-level
interventions, such as contact tracing in
which the entire family is offered testing if
one family member tests positive, may
prove valuable in developing countries.
Data from Uganda found household-
member and door-to-door testing strate-
gies relatively effective and inexpensive as
compared to stand-alone and hospital-
based strategies [16]. To that end, a South
African program, in which HIV-positive
adults accessing ART clinics view a video
in their local language encouraging them
to have their children tested, resulted in
increased uptake of pediatric testing in the
region. Another approach, in which care-
givers (e.g., grandmothers) collecting gov-
ernment checks are targeted with similar
messages, has also shown promise [17,18].
Moving Forward
Many of the strategies proposed here
have been tried and evaluated; however,
implementing them in a coordinated
fashion in resource-limited settings re-
quires new investments. Provider-initiated
testing in pediatric wards, routine testing
of newborns and infants in immunization
Table 1. Costs of Pediatric ARV for Resource-Limited Settings, 2009.
Pediatric Fixed Dose
Combination FDA Approved Date WHO PQ Date
Cost per Year for
a 10kg Child
a
Per Pack Price
a
(Pack Size)
D4T/3TC/NVP
6/30/50 Aug 13 2007 Apr 23 2008 $60 $2.49 (60s)
12/60/100 $54 $4.54 (60s)
D4T/3TC
6/30 Jun 19 2008 – $48 $2.00 (60s)
12/60 $41 $3.42 (60s)
AZT/3TC/NVP – Oct 26 2009 $108 $4.50 (60s)
AZT/3TC July 23 2009 May 25 2009 $80 $3.33 (60s)
ABC/3TC Dec 19 2008 Oct 26 2009 $180 $7.50 (60s)
Based on ref. [21].
aCosts based on Clinton Foundation HIV/AIDS Initiative 2009 ceiling prices http://www.clintonfoundation.org/files/chaiarvpricelistaugust2009english.pdf.
doi:10.1371/journal.pmed.1000285.t001
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ing have all been attempted in sub-
Saharan Africa. What is needed now is a
more coordinated effort at the national
level to ensure that infected children
known to be exposed to HIV and those
missed by PMTCT are identified and
linked to care. Although challenging,
especially when one weighs the parents’
right to confidentiality against the child’s
right to care, a standardized approach to
childhood testing is feasible. Indeed, in the
US many states perform mandatory test-
ing of newborns, allowing the clinician to
offer postnatal ARV prophylaxis to the
index case, comprehensive HIV care to
the mother, and early treatment to the
infected child, with resultant near-elimi-
nation of pediatric HIV mortality and
mother-to-child transmission [19]. Finally,
while the costs of establishing routine
pediatric testing are not insignificant, they
pale in comparison to the societal costs of
delayed diagnosis and increased child
mortality. Given the challenges of scaling
up ART treatment services in resource-
limited settings, we believe the targeted
approaches described above may be a
cost-effective, first strategy to decreasing
the pediatric treatment gap in many
countries and as with other prevention
efforts, should be based on the local
epidemiology of the epidemic. It is clear
that new approaches and a coordinated
response to testing children are necessary
to close this gap. The global public health
community should make this an urgent
priority. Anything less is unacceptable.
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